Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durbin Letter To USPlabs Targets Latest Supplement Adulterant

This article was originally published in The Tan Sheet

Executive Summary

USPlabs is under the spotlight again as perennial supplement industry critic Sen. Dick Durbin inquires about the firm’s adverse event records and other regulatory credentials. The latest supplement controversy could bolster Durbin’s efforts to tighten supplement regulations.

You may also be interested in...



Kratom In Supplements Reaches Dead End On DEA Direct Regulatory Path

DEA says more kratom was seized from US firms in the first half of 2016 than in any previous year, but the seizures came two years after FDA imposed an import alert to stop shipments and three years after the agency stumbled out of the gate in determining whether the ingredient could be used in supplements.

In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill

FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.

US Businessman Ignores Federal, State Regulators’ Warnings, Faces Criminal COVID-19 Fraud Charges

Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel